0001437749-26-015019
SEC filingRevenue more than doubled to $51.0M driven by Zusduri sales volume following its late-2025 launch, boosting gross profit to $46.8M at 91.9% margin and narrowing operating and net losses by over 45% despite elevated cash burn from working capital needs.
UroGen Pharma Ltd. reported strong Q1 FY2026 results with revenue of $51.0 million, up 151.6% from $20.3 million in the prior year quarter. This acceleration stems primarily from increased sales volume of Zusduri, launched late in the second quarter of 2025, as noted in the filing. The revenue surge directly fueled a 161.2% increase in gross profit to $46.8 million, achieving an exceptional 91.9% gross margin. This high margin reflects the company's ability to scale production efficiently, leveraging fixed cost structures as volumes grow in its uro-oncology portfolio.
Despite the top-line momentum, operating income remained negative at -$20.3 million, an improvement of 45.1% from the prior year's -$36.9 million loss, or -39.8% of revenue. The narrowing loss highlights revenue leverage beginning to offset operating expenses, which include investments in commercialization activities. Net income followed suit, improving 46.2% to -$23.6 million from -$43.8 million, with diluted EPS at -$0.47 versus -$0.92, a 48.9% enhancement. These gains demonstrate how the Zusduri launch is driving financial progress even amid ongoing investments.
Cash flow dynamics show the impact of rapid growth. Net cash used in operating activities widened to -$45.3 million from -$42.0 million, contributing to free cash flow of -$45.4 million after minimal $54 thousand in capital expenditures. This increased burn reflects working capital demands from receivables and inventories tied to the sales surge, a common dynamic in scaling commercial biopharma operations. Lower cash and investment balances also contributed to reduced interest and other income, as mentioned in the filing.
Operational context underscores focus on core urology assets amid legal and financing structures like demand waivers and indemnification terms detailed in management discussion. No new guidance or segment breakdowns were provided, but the trajectory signals commercial momentum supporting the path toward sustained profitability as Zusduri penetration expands.